Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
BACKGROUND
Staging evaluations of patients with mycosis fungoides (MF) and Sézary syndrome (SS) are performed to individualize therapy and to predict survival.


OBJECTIVE
Our purpose was to determine the prognostic factors in patients with MF and SS.


METHODS
A retrospective study of 101 patients was performed. For inclusion in the study, patients had to have been evaluated for MF or SS within 6 months of the initial definitive histologic diagnosis. The evaluation included physical examination, chest radiograph, peripheral blood smear, lymph node biopsy, bone marrow biopsy, gallium 67 scan, liver-spleen scan and computed tomography (CT) of the chest, abdomen, and pelvis.


RESULTS
The type of skin disease present at initial diagnosis was a good prognostic indicator of survival and clinical outcome. Univariate adverse prognostic features included hepatosplenomegaly or adenopathy by CT scan, abnormal liver-spleen scan, abnormal gallium scan, adenopathy, and peripheral blood, bone marrow, and lymph node involvement. Independent prognostic factors in multivariate analysis were the type of skin involvement as well as peripheral blood and visceral involvement.


CONCLUSIONS
Our study confirms previous reports that type of skin and peripheral blood and visceral involvement are important prognostic factors in patients with MF or SS. Our results support the finding that patients with T1 stage disease have an excellent survival outlook and clinical outcome.
Toro
J R
JR
Department of Dermatology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Stoll
H L
HL
Stomper
P C
PC
Oseroff
A R
AR
D001853:Bone Marrow / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D009182:Mycosis Fungoides / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000097:blood / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology*; D012878:Skin Neoplasms / Q000473:pathology*; D013154:Spleen / Q000473:pathology; D015996:Survival Rate; D014057:Tomography, X-Ray Computed